Why Exercise Vascular Benefits Vary After Menopause

Aerobic exercise remains a sensible health investment after menopause, even if an artery scan does not always reward the effort. Across 59 randomized trials involving 4,225 postmenopausal women, aerobic training improved blood pressure, resting heart rate, body composition, blood lipids, fasting glucose, and cardiorespiratory fitness in aggregate. Yet exercise has produced uneven results for brachial artery flow-mediated dilation (FMD), a measure of endothelial function. The newest mechanistic evidence suggests the artery's ability to detect the exercise signal is intact; the bottleneck likely lies in making and preserving nitric oxide (NO).

That distinction changes the story. Exercise-induced blood flow creates shear stress along the artery wall. If the endothelium could not sense that force, exercise would deliver a message that the vessel could not hear. But a 2026 crossover study found no evidence of a sex-specific sensing deficit in older postmenopausal women. The more plausible problem is downstream: an endothelium that detects shear stress normally may still struggle to turn it into NO-mediated dilation.

Exercise improves broad risk markers, with uncertain effect sizes

Huynh and colleagues' 2024 systematic review and meta-analysis pooled 59 randomized controlled trials. It found statistically significant improvements in systolic and diastolic blood pressure, resting heart rate, BMI, body-fat percentage, waist measures, LDL and HDL cholesterol, triglycerides, fasting glucose, and cardiorespiratory fitness.

Those findings support aerobic activity for overall cardiometabolic health. They do not tell a woman exactly how much her blood pressure, weight, or cholesterol will change. The review rated the certainty of evidence for every outcome as very low using GRADE. Exercise programs, participant health status, and outcome measurements varied widely. Some studies also confirmed menopausal status imperfectly, and many included women with conditions such as obesity, hypertension, diabetes, or dyslipidemia.

The review's intensity analysis adds an interesting but preliminary wrinkle. Light-intensity exercise at 40% of VO2max or less and vigorous exercise at 60% of VO2max or more were each associated with significant BMI reductions, while moderate-intensity exercise did not reach statistical significance in that subgroup analysis. Small numbers of trials in each intensity subgroup make this a hypothesis for future trials, not a reason to abandon standard moderate exercise.

The vascular result is less dependable

FMD measures how much an artery dilates after a temporary increase in blood flow. It is a vascular biomarker, not a measure of heart attacks, strokes, or survival. Still, impaired endothelial function is relevant because the endothelium helps regulate vascular tone, blood flow, and inflammation.

A 2022 systematic review by Lew et al. found that exercise-training effects on FMD in postmenopausal women were variable and often non-significant. Thompson et al.'s 2024 review placed that inconsistency in a larger problem: vascular exercise research has historically enrolled too few women to establish sex-specific responses with confidence.

Menopause plausibly changes the biology behind the mixed FMD findings. Estrogen withdrawal coincides with lower NO bioavailability. In a mechanistic study, DuBose et al. reported evidence that BH4 deficiency contributes to oxidative-stress-related endothelial dysfunction in menopausal women. BH4 is a required cofactor for endothelial nitric oxide synthase (eNOS). When BH4 is insufficient, eNOS can become "uncoupled," producing superoxide rather than NO. That is an especially unhelpful equipment failure: the enzyme meant to support vasodilation can add oxidative stress instead.

This mechanism is biologically plausible, but it does not prove why any individual woman fails to improve FMD with training. The study did not test whether correcting BH4 deficiency restores aerobic-exercise adaptation. Baseline endothelial health, arterial stiffness, NO substrate availability, oxidative stress, and training dose may all influence the result.

The endothelium still detects exercise-induced shear stress

Oubouchou et al.'s 2026 double-blind randomized crossover trial tested the most intuitive explanation directly. The researchers studied 17 postmenopausal women, average age 66 ± 8 years, and 14 age-matched men, average age 66 ± 6 years. Participants performed graded handgrip exercise at 20% to 80% of maximal voluntary contraction while researchers used high-resolution Doppler ultrasound to track brachial-artery shear rate and FMD.

The key endpoint was endothelial sensitivity: the regression slope linking FMD to shear rate. Under placebo, the slope did not differ significantly between women and men: 0.102 ± 0.055 versus 0.091 ± 0.061 %·s⁻¹, respectively (P=0.603). The experiment therefore did not support impaired shear-stress sensing as the primary sex-specific explanation for inconsistent vascular training responses.

The result is useful, but narrow. This was a small study of 31 people, and the within-group variation was large. Handgrip exercise creates a brief, localized stimulus in the brachial artery; it does not reproduce months of whole-body aerobic training. A non-significant sex difference also does not prove the groups are biologically identical. It means this study did not detect a difference in this endpoint under these conditions.

One folic-acid dose did not fix the response

The same study tested whether acute folic acid could improve shear-stress sensitivity. Participants received 5 mg folic acid or placebo in the crossover design. Folic acid did not improve the slope in women, whose value was 0.099 ± 0.062 %·s⁻¹ after folic acid (P=0.887 versus placebo), or in men, whose value was 0.102 ± 0.083 %·s⁻¹ (P=0.697).

Folate-related pathways can support BH4 preservation and eNOS coupling, which made the experiment reasonable. But a single dose cannot be treated as a test of long-term correction for years of estrogen-deficiency-related oxidative stress. Evidence for the specific 5-MTHF–BH4 pathway also includes a trial in patients with cirrhosis, a population with very different biology from postmenopausal women. The appropriate conclusion is limited: acute 5 mg folic acid did not improve this short-term, localized shear-sensitivity measure.

NO-augmenting approaches have more consistent short-term vascular results

Dietary nitrate offers a different route to NO. It uses the nitrate-nitrite-NO pathway and can bypass eNOS. In a randomized, double-blind, placebo-controlled crossover study of 12 healthy early-postmenopausal women, Somani et al. found that a single nitrate-rich beetroot-juice dose protected against endothelial ischemia-reperfusion injury. A separate randomized, placebo-controlled, double-blind crossover trial studied 24 women—12 early and 12 late postmenopausal—and found that nitrate-rich beetroot juice, providing 600 mg nitrate in 140 mL, improved adjusted FMD responses to ischemia-reperfusion injury relative to nitrate-depleted placebo.

Longer-term data remain small but point in the same direction. A 2025 trial randomized 16 postmenopausal women aged 60 to 85 years to daily nitrate-rich beetroot extract (8.8 mmol nitrate; n=8) or nitrate-depleted extract (0.7 mmol; n=8) for 12 weeks. The nitrate group improved lower-limb conduit-artery function and serum angiogenic potential. These are vascular and laboratory endpoints, not evidence that beetroot prevents cardiovascular events.

L-citrulline addresses a separate constraint: availability of L-arginine, the eNOS substrate. In a four-week randomized trial of 25 hypertensive postmenopausal women, 10 g per day of L-citrulline increased serum L-arginine by 13 ± 2 versus −2 ± 2 µmol/L with placebo (P<0.01) and improved FMD by 1.4 ± 2.0% versus −0.5 ± 1.7% (P=0.03). A randomized crossover trial in 21 healthy postmenopausal women also found vascular benefits after four weeks of two 360 mL servings of 100% watermelon juice daily compared with an isocaloric placebo. Citrulline plus glutathione has also improved endothelial function and blood-pressure reactivity in postmenopausal women.

These interventions do not establish that BH4 deficiency is the only mechanism, or even the dominant one in every woman. Citrulline and glutathione may help by improving substrate availability and limiting NO degradation. Their results fit a model with several NO-limiting pathways rather than one universal defect.

What to do with this evidence

Keep aerobic exercise at the center of a postmenopausal health plan. The broad cardiometabolic evidence is favorable, even though its exact effect sizes remain uncertain. Do not use FMD alone as a report card for whether training "worked." Its response varies, and preserved endothelial function is not uniform after menopause: Darvish et al. found preserved endothelial function among women with late-onset menopause, reinforcing that the postmenopausal category contains meaningful biological variation.

Dietary nitrate has the most consistently positive vascular-specific trial results in this evidence base, while L-citrulline has smaller but direct supportive trials, especially in hypertensive women. Both are complements to exercise, not replacements for it. Acute folic acid has no support as a vascular quick fix. Hormonal treatment can improve endothelial function in meta-analyzed tibolone trials, but hormone decisions require an individualized clinical discussion because their benefits and risks extend far beyond FMD.

The practical lesson is less glamorous than a supplement stack: train consistently, track the outcomes that matter to you, and treat vascular supplements as targeted possibilities—not proof that one beetroot drink repairs menopause-related vascular biology.